Business Trends– category –
-
Kincell Bio Accelerates Cell Therapy Programs from Clinical Development to Commercialization with Comprehensive CDMO Services
Kincell Bio (company website) USA Overview Kincell Bio offers comprehensive and reliable Contract Development and Manufacturing Organization (CDMO) services, supporting cell therapy programs from early clinical development through commer... -
Sana Biotechnology Advances Phase 1 Clinical Trial for Immunosuppression-Free iPSC-Derived Islet Cell Therapy UP421 for Type 1 Diabetes
AAII USA Overview Sana Biotechnology is actively progressing its Phase 1 clinical trial for UP421, an allogeneic islet cell product engineered with its Hypoimmune Platform (HIP) technology for type 1 diabetes, aiming to eliminate the nee... -
EU Approves Itvisma: Single-Dose Gene Therapy Redefines SMA Treatment for Broad Patient Population Aged 2+
BioSpace (via Novartis press release) Europe Overview Novartis' gene therapy Itvisma® (onasemnogene abeparvovec) has received European Commission approval for children, adolescents, and adults aged 2 years and older with 5q spinal muscul... -
iPSC-Derived Off-the-Shelf CAR T Therapy FT819 Shows Promising Safety and Efficacy Signals for Treatment-Resistant Systemic Sclerosis at ISSCR 2026
News-Medical.Net - An AZoNetwork Site USA Overview Preliminary clinical data for FT819, an iPSC-derived CAR T-cell therapy targeting treatment-resistant systemic sclerosis, were presented at the ISSCR 2026 Annual Meeting. FT819 is manufa... -
First-in-Human Pluripotent Stem Cell-Derived Neural Stem Cell Therapy for Huntington’s Disease (Regen4HD) Reports Phase 1b/2a Updates at ISSCR 2026
PharmaTimes USA Overview Updates from the first-in-human Phase 1b/2a clinical trial of Regen4HD, a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease, were presented at the ISSCR 2026 Annual Meeting. This lan... -
MSC-Derived Exosomes Emerge as Promising Cell-Free Regenerative Therapies, Driving Active Research in Arthritis, Chronic Wounds, and Inflammatory Diseases
Vertex AI Search USA Overview Mesenchymal Stem Cell (MSC)-derived exosomes are garnering significant attention in regenerative medicine as a cell-free therapeutic alternative, capable of delivering MSCs' potent regenerative and immunomod... -
CRISPR Gene Therapies Expand Beyond Initial FDA Approvals, Advancing to Late-Stage Trials for Diverse Indications
Ubie Doctor's Note USA Overview As of mid-2026, two CRISPR gene therapies, Casgevy (for sickle cell disease and beta-thalassemia) and EDIT-101 (for Leber congenital amaurosis type 10), have received FDA approval, establishing foundationa... -
North American VC Investment Hits Record $392 Billion in H1 2026, Driven by AI Mega-Rounds; SpaceX IPOs at $75B
TokenPost USA Overview In the first half of 2026, North American startups secured a record $392 billion in venture capital funding, predominantly driven by AI-led mega-rounds. The second quarter alone saw $137.2 billion invested, the sec... -
June 2026 AI Startup Funding: China’s DeepSeek Raises Over $7.4B at >$50B Valuation, DayOne DC Secures $4.5B for AI Data Centers
Intellizence Unknown Overview June 2026 startup funding trends reveal continued massive investments in AI, infrastructure, and robotics. Notably, Chinese AI startup DeepSeek secured over $7.4 billion in its inaugural funding round, achie... -
Major Funding Rounds Active in AI, Energy, and Biotech: Joulent Secures $1.75B, Together AI Raises $800M for Open-Source AI Infrastructure
Crunchbase News USA Overview Despite a holiday-shortened week, U.S. startups announced significant funding across AI, energy, and biotech sectors. Houston-based Joulent secured $1.75 billion in strategic funding, while Together AI, an in...
